To define prognostic groups for recurrence-free survival in breast cancer, assess relative effects of prognostic factors, and examine the influence of treatment variations on recurrence-free survival in patients with similar prognostic-factor profiles.
INTRODUCTION
Breast cancer is the most common malignancy diagnosed among women and the second leading cause of cancer mortality in the United States.
1 In 2004, approximately 215,990 new cases of female invasive breast cancer will be diagnosed in the United States, and 40,110 women will die of the disease.
1 A decline in breast cancer mortality rates has been observed since 1990.
2,3 Results from two large population-based studies suggest the decline is due to adjuvant tamoxifen treatment in women older than 50 years and adjuvant chemotherapy in women younger than 50 years. 4, 5 Still, patients treated with adjuvant chemotherapy or tamoxifen present great heterogeneity in terms of recurrence-free survival, suggesting that patient and/or tumor characteristics may influence outcome more strongly than modifications in standard therapeutic approaches. An analysis of the association of recurrence-free survival (RFS) with patient and tumor characteristics, as well as treatment-related variables, is necessary to assure reliable evaluation of new approaches for treatment of breast cancer.
The goals of the current study, which uses a nonparametric statistical technique known as recursive partitioning (RP), are to (1) analyze the relative contributions of patient and tumor-related prognostic factors to the RFS of patients with stage I-III breast 
